Intracranial complete remissions in an aumolertinib-treated EGFR mutation-positive non-small cell lung cancer (NSCLC) patient with symptomatic brain metastases and Eastern Cooperative Oncology Group performance status (ECOG PS) up to 4: a case report

BACKGROUND: Brain metastases happen in approximately 70% of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients. It negatively impacts the survival and quality of life, with the median survival time for untreated patients is just 2.9 months. Nevertheless, no ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, Xiu, Wu, Yuanhang, Liu, Jiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007882/
https://www.ncbi.nlm.nih.gov/pubmed/36915577
http://dx.doi.org/10.21037/tcr-22-1614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007882/
https://www.ncbi.nlm.nih.gov/pubmed/36915577
http://dx.doi.org/10.21037/tcr-22-1614

Ejemplares similares